October 9, 2025 — Beijing: Beijing GoBroad Hospital have officially issued China’s first in-hospital prescription for Lazertinib Mesylate Tablets.

The prescription was written by Dr. Lili Qin, marking the first clinical use of this third-generation EGFR-TKI in combination with Amivantamab, which had also achieved its first nationwide hospital prescription at GoBroad earlier this year.

This milestone brings new hope for a patient with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion, and signifies that China's frontline treatment for EGFR-mutant NSCLC has officially entered the era of “dual-antibody + TKI” synergy—further highlighting GoBroad's leadership in the clinical translation of innovative therapies.

Precision Breakthrough: A New Option for Patients at a Crossroads

The treated patient had undergone lung cancer surgery two years ago but was recently found to have disease progression with multiple metastases—facing resistance to conventional therapy.

Genetic testing confirmed an EGFR exon 19 deletion, a classic sensitizing mutation, yet post-surgical metastasis demanded a stronger and more durable treatment strategy.

The multidisciplinary team (MDT) at Beijing GoBroad Hospital’s Thoracic Oncology and Tumor Immunotherapy Departments quickly convened, carefully reviewed the patient’s clinical and molecular profile, and ultimately determined a dual-target regimen combining Lazertinib and Amivantamab.

This success was no coincidence. Amivantamab had already achieved its first in-hospital prescription in China at GoBroad in May 2025, and just five months later, Lazertinib followed suit — a reflection of GoBroad’s “innovation speed” powered by a well-established mechanism for introducing novel therapies and a mature clinical application framework.

Evidence-Based Excellence: Redefining Survival Outcomes

“The approval of Lazertinib combined with Amivantamab represents a landmark breakthrough supported by the Phase III MARIPOSA study, setting a new treatment standard for EGFR-mutated advanced NSCLC,”— said Dr. Shasha Wang, Deputy Director of Thoracic Oncology and Tumor Immunotherapy at Beijing GoBroad Hospital.

Key clinical findings demonstrate remarkable advantages of the combination therapy:

• Record-breaking survival benefit: Among Asian patients, this first-line regimen achieved a median overall survival (OS) of 57.7 months, extending life expectancy by more than 12 months compared to standard therapy. At 37.8 months, 56% of patients receiving the combination were still alive — 12% higher than the control group.
• Multi-dimensional efficacy improvement: The complete response rate doubled compared with monotherapy, and the median progression-free survival (PFS) reached 23.7 months, extending to 27.5 months in Asian subgroups, reducing the risk of progression or death by 35%.

 Research-Driven Excellence: GoBroad Accelerating Innovation into Clinical Practice

The successful rollout of the nation's first Lazertinib in-hospital prescription once again underscores Beijing GoBroad Hospital’s strong foundation as a research-driven medical institution.

From Amivantamab to Lazertinib, from rare-disease drugs to next-generation anti-tumor therapies, GoBroad is actively translating global innovations into real-world clinical benefits—bringing cutting-edge treatments to patients faster and upholding the principle of “patient needs first.”

Looking ahead, GoBroad will continue leveraging its integrated clinical and research strengths, accelerating the translation of breakthrough therapies, and striving to bring longer survival and better quality of life to cancer patients worldwide.